22nd Century Group, Inc. (:XXII) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm. The stock boasts a consensus analyst “Buy” rating with the consensus recommendation standing at 2.00. This is according to all covering research brokerage firms taken into consideration by First Call. The consensus price target of $3.50 also implies significant upside from the current price of $2.47.
22nd Century Group, Inc. (:XXII)’s shares may have a significant upside to the consensus target of 3.50, but how has it been performing relative to the market? The stock’s price is 2.47 and their relative strength index (RSI) stands at 80.13. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.
22nd Century Group, Inc. (:XXII) shares are moving 24.75% trading at $2.47 today.
Stock research firms currently have a positive stance on shares of Cara Therapeutics, Inc. (NASDAQ:CARA). Analysts are projecting that the stock will reach $25.14 on a short term (1 year) basis.
The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 1.90. This is based on the research brokerage reports taken into consideration by Thomson Reuters.
At the time of writing, the stock was trading at $16.34. This represents a change from most recent open price of 12.69%. In terms of performance, year to date, the stock is 75.89%. The monthly stock performance comes in at 8.50%. For the quarter, shares are performing at 11.23%. Weekly performance analysis shows the equity at 16.38%.
In taking a look at technical levels, shares are trading -2.90% away from the 50 day simple moving average and 15.44% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -42.67% away from it’s 52- week high and 222.29% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Cara Therapeutics, Inc.’s RSI stands at 55.60. In looking at volatility levels, the shares saw weekly volatility of 7.71% and 7.34% over the past month.